Advanced Solid Tumor Clinical Trials in Cincinnati, Ohio

10 studies are recruiting for advanced solid tumor in Cincinnati, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

   A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati Medical Center, Cincinnati, Ohio

   Locations

   21 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT06859762 on ClinicalTrials.gov

2. Study of SGN1 in Patients With Advanced Solid Tumor

   Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Rationale:The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent.…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   University of Cincinnati Cancer Center, Cincinnati, Ohio

   Locations

   8 in total

   Run by

   Guangzhou Sinogen Pharmaceutical Co., Ltd

   See if you can join NCT05038150 on ClinicalTrials.gov

3. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati Medical Center, Cincinnati, Ohio

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

4. A Study of PYX-201 in Advanced Solid Tumors

   The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati Medical Center, Cincinnati, Ohio

   Locations

   29 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT05720117 on ClinicalTrials.gov

5. A Study of DB-1310 in Advanced/Metastatic Solid Tumors

   This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati, Ohio

   Locations

   24 in total

   Run by

   DualityBio Inc.

   See if you can join NCT05785741 on ClinicalTrials.gov

6. FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

   This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Hematology Care Clinial Trials, Cincinnati, Ohio

   Locations

   14 in total

   Run by

   Fate Therapeutics

   See if you can join NCT06241456 on ClinicalTrials.gov

7. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

   This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Christ Hospital, Cincinnati, Ohio

   Locations

   14 in total

   Run by

   Volastra Therapeutics, Inc.

   See if you can join NCT05902988 on ClinicalTrials.gov

8. A Study of LM-24C5 For Advanced Solid Tumors

   To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Christ Hospital, Cincinnati, Ohio

   Locations

   6 in total

   Run by

   LaNova Medicines Limited

   See if you can join NCT06187402 on ClinicalTrials.gov

9. Study of SGR-3515 In Participants With Advanced Solid Tumors.

   The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati Medical Center, Cincinnati, Ohio

   Locations

   14 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT06463340 on ClinicalTrials.gov

10. A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

    This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination with fulvestrant in subjects with advanced solid tumors. The study wil…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Linder Research Center at The Christ Hospital, Cincinnati, Ohio

    Locations

    6 in total

    Run by

    Edgewood Oncology Inc.

    See if you can join NCT04872166 on ClinicalTrials.gov